Detalhe da pesquisa
1.
Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity.
Exp Parasitol
; 150: 44-55, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25637784
2.
Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.
Exp Parasitol
; 128(1): 9-17, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21276444
3.
Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity.
Exp Parasitol
; 126(2): 135-45, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20417202
4.
Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.
PLoS Negl Trop Dis
; 8(3): e2751, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24675711
5.
Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate.
PLoS Negl Trop Dis
; 7(10): e2491, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24147170
6.
Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.
PLoS Negl Trop Dis
; 7(4): e2174, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23638195
7.
Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
Immunol Lett
; 148(2): 117-25, 2012 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23085605
8.
In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.
PLoS Negl Trop Dis
; 5(9): e1295, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21909442
9.
Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Vaccine
; 22(15-16): 1930-40, 2004 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-15121305